An Eight-Week, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Saredutant (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 25 Apr 2018 This study has been completed in Estonia.
- 22 Dec 2008 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
- 22 Dec 2008 Actual number of patients (467) added as reported by ClinicalTrials.gov.